Oncternal Revenue and Competitors
Estimated Revenue & Valuation
- Oncternal's estimated annual revenue is currently $1.6M per year.
- Oncternal's estimated revenue per employee is $84,000
Employee Data
- Oncternal has 19 Employees.
- Oncternal grew their employee count by -52% last year.
Oncternal's People
| Name | Title | Email/Phone |
|---|---|---|
1 | President & CEO | Reveal Email/Phone |
2 | CFO | Reveal Email/Phone |
3 | SVP Corporate Development | Reveal Email/Phone |
4 | VP, Technical Operations & Alliance Management | Reveal Email/Phone |
5 | SVP, Regulatory Affairs and Quality | Reveal Email/Phone |
6 | Head Information Technology | Reveal Email/Phone |
7 | Head Biometrics & Data Sciences | Reveal Email/Phone |
8 | General Counsel & Corporate Secretary | Reveal Email/Phone |
9 | SVP, HR | Reveal Email/Phone |
10 | General Counsel | Reveal Email/Phone |
Oncternal Competitors & AlternativesAdd Company
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $223.4M | 1116 | 5% | $65M | N/A |
#2 | $41.9M | 272 | 18% | N/A | N/A |
#3 | $55.8M | 314 | -5% | $102.6M | N/A |
#4 | $3.4M | 32 | -24% | $21.3M | N/A |
#5 | $35.7M | 237 | 0% | $42.9M | N/A |
#6 | $3.8M | 36 | -27% | $35M | N/A |
#7 | $0.9M | 11 | N/A | N/A | N/A |
#8 | $13.9M | 99 | -9% | N/A | N/A |
#9 | $18.2M | 130 | 0% | $96.4M | N/A |
#10 | $6.2M | 51 | -25% | $75.6M | N/A |
What Is Oncternal?
Oncternal Therapeutics is a clinical-stage oncology company developing a diverse pipeline of treatments for cancers with critical unmet medical need. Oncternal focuses drug development on promising yet untapped biological pathways implicated in cancer progression. The pipeline includes cirmtuzumab, a monoclonal antibody in Phase 1/2 development that inhibits the ROR1 receptor in various hematologic cancers; TK-216, a small-molecule in Phase 1 development that inhibits ETS-family oncoproteins, as a treatment for Ewing sarcoma, a rare pediatric cancer; and a CAR-T therapy that targets ROR1 currently in preclinical development as a potential treatment for solid tumors and hematologic cancers. Based in San Diego, Oncternal is committed to advancing its pipeline rapidly and efficiently to bring patients a new wave of first-in-class cancer treatments.
keywords:N/A
N/A
Total Funding
19
Number of Employees
$1.6M
Revenue (est)
-52%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Oncternal News
Oncternal Therapeutics Deprioritizes Development of ONCT-216 to Focus Resources on Phase 3 Trial for Zilovertamab in the Treatment of Mantle...
Oncternal Therapeutics Inc. said it has deprioritized development of its potential Ewing sarcoma treatment, ONCT-216, to reallocate...
Oncternal will reallocate resources to its global phase 3 study of its investigational anti-ROR1 monoclonal antibody zilovertamab for the...
Other Companies in San Diego
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $1.7M | 19 | -10% | N/A |
#2 | $2.3M | 19 | 27% | N/A |
#3 | $15M | 19 | 0% | $67.5M |
#4 | $1.7M | 19 | 6% | $9.7M |
#5 | $1.9M | 19 | 0% | N/A |